Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: Results through 2 years of the go-forward study extension

Journal of Rheumatology

Volumn 40, Issue 7, 2013, Pages 1097-1103

  Keystone, Edward C ^a   Genovese, Mark C ^b   Hall, Stephen ^c   Miranda, Pedro C ^d   Bae, Sang Cheol ^e   Palmer, William ^f   Wu, Zhong ^g   Xu, Stephen ^h   Hsia, Elizabeth C ^h  

^a UNIVERSITY OF TORONTO   (Canada)

^b STANFORD UNIVERSITY   (United States)

^c Medicine Rheumatology   (United States)

^d UNIVERSITY OF CHILE   (Chile)

^e Hanyang Institute of Bioscience and Biotechnology   (South Korea)

^f Westroads Medical Group   (United States)

^g Biostatistical Manager ^*  (United States)

^h JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Efficacy; Longterm; Rheumatoid Arthritis; Safety; Tumor Necrosis Factor Antagonist

Indexed keywords

C REACTIVE PROTEIN; GOLIMUMAB; METHOTREXATE; PLACEBO;

AMERICAN COLLEGE OF RHEUMATOLOGY 20; ANAPHYLAXIS; ARTHROPATHY; ARTICLE; BASAL CELL CARCINOMA; BREAST CANCER; BRONCHITIS; CONTROLLED STUDY; COUGHING; DAS28; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; FOLLOW UP; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; INFECTION; INJECTION SITE ERYTHEMA; INJECTION SITE REACTION; JOINT SWELLING; JOINT TENDERNESS; LYMPHOMA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SCORING SYSTEM; SERUM SICKNESS; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; TUBERCULOSIS; TUBERCULOUS PERITONITIS; TUBERCULOUS PLEURISY; UPPER RESPIRATORY TRACT INFECTION;

EFFICACY; LONGTERM; RHEUMATOID ARTHRITIS; SAFETY; TUMOR NECROSIS FACTOR ANTAGONIST;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84879891418     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.120584     Document Type: Article

References (18)

1. Keystone EC, Genovese MC, Klareskog L, Hsia EC, Hall ST, Miranda PC, et al. Golimumab, a human antibody to tumour necrosis factor alpha given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: The GO-FORWARD Study. Ann Rheum Dis 2009;68:789-96.
2. Keystone E, Genovese MC, Klareskog L, Hsia EC, Hall ST, Miranda PC, et al. Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study. Ann Rheum Dis 2010;69:1129-35.
3. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
4. Conaghan PG, Emery P, Ostergaard M, Keystone EC, Genovese MC, Hsia EC, et al. Assessment by MRI of inflammation and damage in rheumatoid arthritis patients with methotrexate inadequate response receiving golimumab: Results of the GO-FORWARD trial. Ann Rheum Dis 2011;70:1968-74.
5. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
6. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts: Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
7. Wells G, Becker JC, Teng J, Dougados M, Schiff M, Smolen J, et al. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis 2009;68:954-60.
8. Aletaha D, Ward MM, Machold KP, Nell VP, Stamm T, Smolen JS. Remission and active disease in rheumatoid arthritis: Defining criteria for disease activity states. Arthritis Rheum 2005;52:2625-36.
9. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45.
10. Emery P, Fleischmann R, van der Heijde D, Keystone EC, Genovese MC, Conaghan PG, et al. The effects of golimumab on radiographic progression in rheumatoid arthritis: Results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy. Arthritis Rheum 2011;63:1200-10.
11. van der Heijde DM, van Leeuwen MA, van Riel PL, Koster AM, van 't Hof MA, van Rijswijk MH, et al. Biannual radiographic assessments of hands and feet in a three-year prospective followup of patients with early rheumatoid arthritis. Arthritis Rheum 1992;35:26-34.
12. National Cancer Institute. The Surveillance, Epidemiology, and End Results (SEER) Database. 2007. [Internet. Accessed March 27, 2013.] Available from: Http://seer.cancer.gov/statistics
13. Zhuang Y, Xu Z, Frederick B, de Vries DE, Ford JA, Keen M, et al. Golimumab pharmacokinetics after repeated subcutaneous and intravenous administrations in patients with rheumatoid arthritis and the effect of concomitant methotrexate: An open-label, randomized study. Clin Ther 2012;34:77-90.
14. Emery P, Fleischmann RM, Moreland LW, Hsia EC, Strusberg I, Durez P, et al. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum 2009;60:2272-83.
15. Westhovens R, Yocum D, Han J, Berman A, Strusberg I, Geusens P, et al, on behalf of the START Study Group. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: A large, randomized, placebo-controlled trial. Arthritis Rheum 2006;54:1075-86.
16. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275-85.
17. Rahman MU, Strusberg I, Geusens P, Berman A, Yocum D, Baker D, et al. Double-blinded infliximab dose escalation in patients with rheumatoid arthritis. Ann Rheum Dis 2007;66:1233-8.
18. Hsia EC, Schluger N, Cush J, Chaisson RE, Matteson EL, Xu S, et al. Interferon-gamma release assay versus tuberculin skin test across RA, PsA, and AS patients prior to treatment with golimumab, a human anti-TNF antibody. Arthritis Rheum 2012;64:2068-77.